219 related articles for article (PubMed ID: 3264091)
21. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
22. Differences in murine gut-associated lymphoid tissues in generating broadly nonspecific cytotoxic cells in response to interferon alpha A/D and interleukin 2.
Chikkala NF; Gautam SC
Cell Immunol; 1991 Jul; 135(2):418-30. PubMed ID: 2036676
[TBL] [Abstract][Full Text] [Related]
23. Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.
Shau H; Gray JD; Golub SH
Cancer Immunol Immunother; 1988; 27(3):255-60. PubMed ID: 2972366
[TBL] [Abstract][Full Text] [Related]
24. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
25. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
Fox BA; Rosenberg SA
Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
[TBL] [Abstract][Full Text] [Related]
27. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
29. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
30. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
31. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
Brunda MJ; Tarnowski D; Davatelis V
Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 2-induced proliferation of murine natural killer cells in vivo.
Biron CA; Young HA; Kasaian MT
J Exp Med; 1990 Jan; 171(1):173-88. PubMed ID: 1688606
[TBL] [Abstract][Full Text] [Related]
33. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
34. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
Ellis TM; Fisher RI
J Immunol; 1989 Apr; 142(8):2949-54. PubMed ID: 2467946
[TBL] [Abstract][Full Text] [Related]
35. Age related natural killer activity of peripheral blood lymphocytes from healthy subjects and cancer patients. A comparative in vitro study with interleukin-2.
Chakraborty A; Chakraborty NG; Chattopadhyay U
Tumori; 1994 Jun; 80(3):233-7. PubMed ID: 8053083
[TBL] [Abstract][Full Text] [Related]
36. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
37. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
39. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
40. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
